The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
August 3, 2026
View Complete Issue         Table of Contents 2019 
Inqovi for Acute Myeloid Leukemia (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Inqovi for Acute Myeloid Leukemia (online only)
August 3, 2026 (Issue: 1760)
The FDA has approved Inqovi (Taiho Oncology), a fixed-dose combination of the nucleoside metabolic inhibitor decitabine and the cytidine deaminase inhibitor cedazuridine, for use in combination with venetoclax (Venclexta, and generics) for oral...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Inqovi for Acute Myeloid Leukemia (online only)
Article code: 1760e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.